Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease

Tse, Chung Sang; Loftus, Edward V.; Raffals, Laura E.; Gossard, Andrea A.; Lightner, Amy L.

doi:10.1111/apt.14829

Cited by 61 publications

(57 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A retrospective analysis by Tse et al found initial improvement in ALP in patients with PSC and concomitant IBD who were treated with the anti-tumour-necrosis factor alpha (TNF) antibody, adalimumab. 18 However, these findings were not confirmed when PSC patients were treated with another anti-TNF antibody, infliximab. No improvement in liver biochemistry was seen in patients with IBD and concomitant PSC receiving vedolizumab, an α4β7 integrin inhibitor.…”

Section: Primary Scleros Ing Chol Ang Itismentioning

confidence: 97%

“…The potential impact of IBD therapies on PSC were evaluated based on the strong association between PSC and IBD. A retrospective analysis by Tse et al found initial improvement in ALP in patients with PSC and concomitant IBD who were treated with the anti‐tumour‐necrosis factor alpha (TNF) antibody, adalimumab . However, these findings were not confirmed when PSC patients were treated with another anti‐TNF antibody, infliximab.…”

Section: Primary Sclerosing Cholangitismentioning

confidence: 99%

“…However, these findings were not confirmed when PSC patients were treated with another anti‐TNF antibody, infliximab. No improvement in liver biochemistry was seen in patients with IBD and concomitant PSC receiving vedolizumab, an α4β7 integrin inhibitor . A recent trial investigated the feasibility and safety of faecal microbiota transplantation (FMT) in patients with PSC.…”

Section: Primary Sclerosing Cholangitismentioning

confidence: 99%

“…No improvement in liver biochemistry was seen in patients with IBD and concomitant PSC receiving vedolizumab, an α4β7 integrin inhibitor. 18 A recent trial investigated the feasibility and safety of faecal microbiota transplantation (FMT) in patients with PSC. Ten patients with PSC and concomitant IBD and an ALP >1.5 × ULN were included and received a single FMT via colonoscopy.…”

Section: Primary Scleros Ing Chol Ang Itismentioning

confidence: 99%

See 3 more Smart Citations

The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality

Engel

Taubert

Jaeckel

et al. 2020

Liver International

View full text Add to dashboard Cite

Autoimmune liver diseases (AILD), namely autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are rare diseases. These days, patients with PBC almost never require liver transplantation. When treated early with ursodeoxycholic acid patients have a normal life expectancy if the disease is diagnosed at an early stage and the patients respond to treatment. Patients with AIH often go into remission with first‐line therapy including corticosteroids alone or in combination with azathioprine. Nevertheless, about one quarter of patients already developed cirrhosis at diagnosis. Those who do not respond to first line standard of care (SOC) have significant liver‐related morbidity and mortality. No approved second‐ or third‐line treatments are available and the drugs are selected based on limited case series and personal experience. Larger trials are needed to develop efficient therapies for difficult‐to‐treat AIH patients. No treatment has been found to alter the natural course of disease in patients with PSC except for liver transplantation. Identifying PSC patients at risk of developing cholangiocarcinoma (CCA) is another unmet need. Current research in all AILD including AIH, PBC and PSC, focuses on improving our understanding of the underlying disease process and identifying new therapeutic targets to decrease morbidity and mortality.

show abstract

Section: Primary Scleros Ing Chol Ang Itismentioning

confidence: 97%

Section: Primary Sclerosing Cholangitismentioning

confidence: 99%

Section: Primary Sclerosing Cholangitismentioning

confidence: 99%

Section: Primary Scleros Ing Chol Ang Itismentioning

confidence: 99%

See 2 more Smart Citations

The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality

Engel

Taubert

Jaeckel

et al. 2020

Liver International

View full text Add to dashboard Cite

show abstract

“…Tse et al. have evaluated the effect of vedolizumab, adalimumab, and infliximab in patients with PSC and IBD . The authors evaluated 88 IBD/PSC patients treated with biologic agents, and compared pre‐ and post‐treatment hepatic biochemistry at ≤3 months before with 6‐8 months and 12‐14 months after biologic initiation.…”

mentioning

confidence: 99%

Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise?

Kotze

2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Pathophysiologic Basis for Alternative Therapies for Cholestasis

2020

View full text Add to dashboard Cite

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease

Abstract: Current evidence suggests that biological therapies used for the treatment of IBD are not effective treatments for PSC. Further study is needed to elucidate any potential beneficial effect of adalimumab on PSC.

Cited by 61 publications

References 22 publications

The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality

The future of autoimmune liver diseases – Understanding pathogenesis and improving morbidity and mortality

Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise?

Pathophysiologic Basis for Alternative Therapies for Cholestasis

Contact Info

Product

Resources

About